Trinity Biotech (TRIB) Amortization - Deferred Charges (2016 - 2024)
Trinity Biotech's Amortization - Deferred Charges history spans 10 years, with the latest figure at $4.3 million for Q4 2024.
- On a quarterly basis, Amortization - Deferred Charges rose 83.31% to $4.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.9 million, a 36.32% decrease, with the full-year FY2024 number at -$9.6 million, down 186.54% from a year prior.
- Amortization - Deferred Charges hit $4.3 million in Q4 2024 for Trinity Biotech, up from -$3.1 million in the prior quarter.
- Over the last five years, Amortization - Deferred Charges for TRIB hit a ceiling of $4.3 million in Q4 2024 and a floor of -$3.1 million in Q3 2024.
- Historically, Amortization - Deferred Charges has averaged $250416.5 across 5 years, with a median of -$598318.0 in 2021.
- Biggest five-year swings in Amortization - Deferred Charges: skyrocketed 508.5% in 2022 and later tumbled 229.2% in 2024.
- Tracing TRIB's Amortization - Deferred Charges over 5 years: stood at -$1.2 million in 2020, then skyrocketed by 345.18% to $3.0 million in 2021, then dropped by 20.19% to $2.4 million in 2022, then fell by 2.42% to $2.3 million in 2023, then skyrocketed by 83.31% to $4.3 million in 2024.
- Business Quant data shows Amortization - Deferred Charges for TRIB at $4.3 million in Q4 2024, -$3.1 million in Q3 2024, and $2.3 million in Q4 2023.